Tumour dissemination in multiple myeloma disease progression and relapse: A potential therapeutic target in high-risk myeloma
Files
(Published version)
Date
2020
Authors
Zeissig, M.N.
Zannettino, A.C.W.
Vandyke, K.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Cancers, 2020; 12(12):3643-1-3643-20
Statement of Responsibility
Mara N. Zeissig, Andrew C. W. Zannettino and Kate Vandyke
Conference Name
Abstract
Multiple myeloma (MM) is a plasma cell (PC) malignancy characterised by the presence of MM PCs at multiple sites throughout the bone marrow. Increased numbers of peripheral blood MM PCs are associated with rapid disease progression, shorter time to relapse and are a feature of advanced disease. In this review, the current understanding of the process of MM PC dissemination and the extrinsic and intrinsic factors potentially driving it are addressed through analysis of patient-derived MM PCs and MM cell lines as well as mouse models of homing and dissemination. In addition, we discuss how patient cytogenetic subgroups that present with highly disseminated disease, such as t(4;14), t(14;16) and t(14;20), suggest that intrinsic properties of MM PC influence their ability to disseminate. Finally, we discuss the possibility of using therapeutic targeting of tumour dissemination to slow disease progression and prevent overt relapse.
School/Discipline
Dissertation Note
Provenance
Description
Published: 4 December 2020
Access Status
Rights
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).